Skip to main content
PCI Biotech Holding logo

PCI Biotech Holding — Investor Relations & Filings

Ticker · PCIB ISIN · NO0010405640 LEI · 5967007LIEEXZXFIGG77 OL Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2019-07-22 Regulatory Filings
Country NO Norway
Listing OL PCIB

About PCI Biotech Holding

https://www.pcibiotech.no/

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalization (PCI) technology. This platform is a drug and nucleic acid delivery system designed to enhance the intracellular delivery of therapeutic molecules. The company's development programs are focused on applications in immunotherapy, dermatology, and bioprocessing for the manufacturing of viral vectors. A primary therapeutic area for the technology is cancer, where it aims to improve the efficacy of novel and existing treatments.

Recent filings

Filing Released Lang Actions
PCI Biotech: Extension of preclinical research collaboration agreement with a top-10 large pharma company
Regulatory Filings Classification · 95% confidence The document is a press release announcing the extension of a preclinical research collaboration between PCI Biotech and an undisclosed pharmaceutical company. It does not fit into specific categories like financial reports, dividend announcements, or board changes. As it is a general corporate announcement regarding business operations and partnerships, it falls under the 'Regulatory Filings' (RNS) category as a catch-all for miscellaneous corporate news.
2019-07-22 English
PCI Biotech: Extension of preclinical research collaboration agreement with a top-10 large pharma company
Regulatory Filings Classification · 95% confidence The document is a press release announcing the extension of a preclinical research collaboration between PCI Biotech and an undisclosed pharmaceutical company. It does not fit into specific categories like financial reports, dividend announcements, or board changes. As it is a general corporate announcement regarding business operations and partnerships, it falls under the 'Regulatory Filings' (RNS) category as a catch-all for miscellaneous corporate news.
2019-07-22 English
PCI Biotech: Extension of preclinical research collaboration agreement with a top-10 large pharma company
M&A Activity Classification · 99% confidence The document is a short press release dated July 22, 2019, announcing an extension of a preclinical research collaboration between PCI Biotech and an undisclosed pharma company regarding technology evaluation. It contains contact information, boilerplate 'About' sections, and forward-looking statements, typical of a corporate news announcement. Since it is not a full financial report (10-K, IR), a specific financial event (DIV, CAP), or a transcript (CT), and it is an announcement of operational/business news, it best fits the general category for regulatory announcements that don't fit elsewhere, which is Regulatory Filings (RNS). Given its brevity and nature as a news update, RNS is the most appropriate classification, although it could also be considered a general Investor Relations item, RNS serves as the best catch-all for non-standard, non-financial regulatory disclosures.
2019-07-22 English
PCI Biotech: Extension of preclinical research collaboration agreement with a top-10 large pharma company
Regulatory Filings Classification · 100% confidence The document is a press release dated July 22, 2019, announcing the extension of a preclinical research collaboration agreement between PCI Biotech and an undisclosed top-10 pharma company. It details the extension period, the purpose of the research (evaluating synergistic effects and potential enhancement of nucleic acid therapeutics), and provides company background. This type of announcement, detailing strategic business developments, partnerships, or research progress outside of standard financial reporting (like 10-K or ER), typically falls under general regulatory announcements or investor relations news. Since there is no specific category for 'Partnership Announcement' or 'Research Update,' and it is not a formal financial report, a capital change, or a management change, the most appropriate classification is the general regulatory/miscellaneous category, RNS (Regulatory Filings), as per the provided definitions and the nature of the content as a corporate news release.
2019-07-22 English
PCI Biotech to present at IPA World Congress
Regulatory Filings Classification · 95% confidence The document is a short press release (under 5,000 characters) announcing that the company will be presenting at an upcoming industry conference (IPA World Congress). It does not contain the actual presentation slides, nor is it a financial report or regulatory filing of a specific type. It serves as a general corporate announcement regarding company activities, which falls under the 'Regulatory Filings' (RNS) category as a fallback for miscellaneous corporate news.
2019-07-01 English
PCI Biotech to present at IPA World Congress
Regulatory Filings Classification · 95% confidence The document is a short press release (under 5,000 characters) announcing that the company will be presenting at an upcoming industry conference (IPA World Congress). It does not contain the actual presentation slides, nor is it a financial report or regulatory filing of a specific type. It serves as a general corporate announcement regarding company activities, which falls under the 'Regulatory Filings' (RNS) category as a fallback for miscellaneous corporate news.
2019-07-01 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.